ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026
Missed opportunities for maternal immunisation against influenza and COVID-19, Norway, October 2023 to May 2024: a population-based registry study.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vertical Vaccination Against Infant Influenza Hospitalization in a Tropical Setting.JAMA network open · 2026Article
- 2023-2024 COVID-19 vaccination coverage in pregnancy in ten healthcare delivery organizations in the United States.Vaccine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDPregnant women and their newborns are at increased risk of severe outcomes from influenza and COVID-19 infections; maternal vaccination is recommended. However, no routine surveillance of maternal vaccine coverage exists in Norway.AIMTo provide insights into vaccination coverage and timing during pregnancy.METHODSThis population-based registry study included women who gave birth in Norway during 1 October 2023-30 September 2024. Data on influenza and COVID-19 vaccinations administered during 1 October 2023-10 May 2024 were obtained from the national immunisation registry and linked to birth data from the Medical Birth Registry Norway. Cumulative coverage included vaccines administered during pregnancy, with sub-analyses focusing on second and third trimester vaccinations, month of delivery and maternal age.RESULTSOverall influenza vaccination coverage was 29.9% (15,915/53,161), with 22.3% (11,856/53,161) vaccinated in the second or third trimester. Coverage increased from 16.4% (7,287/44,454) in October to 26.4% (12,982/49,170) in November and plateaued thereafter. Coverage peaked among women delivering in February (50.8%; 2,159/4,248) and declined afterwards. COVID-19 vaccination coverage was 12.1% (6,423/53,161) with 10.1% (5,349/53,161) in the second or third trimester, following a similar pattern to influenza. Overall, 11.4% received both vaccines. The lowest uptake (< 19%) was among women aged 25 years or younger.CONCLUSIONCoverage of maternal influenza and COVID-19 vaccinations for 2023/24 remained low, with missed opportunities to reach pregnant women beyond November 2023. Overall, the coverage was lowest among women aged 25 years or younger. Strengthened efforts are needed to increase vaccination coverage among pregnant women and reduce gaps in protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.